|
2025-05-13 |
2025-05-09 |
V
Vente
|
Hickey Benjamin
President, RayzeBio Org.
Dirigeant
|
97
-100.0%
38,01
3 702 USD
|
97
-100.0%
|
38,01
|
3 702 USD
|
|
|
2025-04-29 |
2025-04-25 |
A
Achat
|
Hirawat Samit
EVP,Chief Med.Offr.,Drug Dev.
Dirigeant
|
4 250
+5.4%
47,58
202 215 USD
|
4 250
+5.4%
|
47,58
|
202 215 USD
|
|
|
2025-02-21 |
2025-02-20 |
A
Achat
|
BOERNER CHRISTOPHER S.
Chief Executive Officer
Administrateur exécutif
|
2 000
+1.9%
55,05
110 096 USD
|
2 000
+1.9%
|
55,05
|
110 096 USD
|
|
|
2025-02-19 |
2025-02-14 |
A
Achat
|
Hirawat Samit
EVP,Chief Med.Offr.,Drug Dev.
Dirigeant
|
1 823
+2.9%
54,84
100 000 USD
|
1 823
+2.9%
|
54,84
|
100 000 USD
|
|
|
2024-11-05 |
2024-11-04 |
V
Vente
|
Holzer Phil M
SVP and Controller
Dirigeant
|
700
-5.6%
55,62
38 931 USD
|
700
-5.6%
|
55,62
|
38 931 USD
|
|
|
2024-11-05 |
2024-11-01 |
A
Achat
|
Hirawat Samit
EVP,Chief Med.Offr.,Drug Dev.
Dirigeant
|
1 830
+3.0%
54,68
100 055 USD
|
1 830
+3.0%
|
54,68
|
100 055 USD
|
|
|
2023-12-07 |
2023-12-05 |
A
Achat
|
BOERNER CHRISTOPHER S.
Chief Executive Officer
Dirigeant
|
2 000
+2.5%
49,78
99 560 USD
|
2 000
+2.5%
|
49,78
|
99 560 USD
|
|
|
2023-11-30 |
2023-11-28 |
A
Achat
|
BOERNER CHRISTOPHER S.
Chief Executive Officer
Dirigeant
|
3 071
+4.0%
48,86
150 049 USD
|
3 071
+4.0%
|
48,86
|
150 049 USD
|
|
|
2023-11-21 |
2023-11-20 |
A
Achat
|
Samuels Theodore R. II
Administrateur non-exécutif
|
8 500
+31.5%
49,81
423 385 USD
|
8 500
+31.5%
|
49,81
|
423 385 USD
|
|
|
2023-08-28 |
2023-08-24 |
V
Vente
|
Powell Ann
EVP, Chief Human Resources
Dirigeant
|
17 986
-39.2%
61,25
1 101 643 USD
|
17 986
-39.2%
|
61,25
|
1 101 643 USD
|
|
|
2023-08-07 |
2023-08-03 |
V
Vente
|
Plenge Robert M
EVP, Chief Research Officer
Dirigeant
|
732
-10.0%
61,14
44 754 USD
|
732
-10.0%
|
61,14
|
44 754 USD
|
|
|
2023-05-04 |
2023-05-03 |
V
Vente
|
VESSEY RUPERT
EVP & President, Research
Dirigeant
|
50 385
-51.3%
67,06
3 378 818 USD
|
50 385
-51.3%
|
67,06
|
3 378 818 USD
|
|
|
2023-02-08 |
2023-02-06 |
V
Vente
|
Powell Ann
EVP, Chief Human Resources
Dirigeant
|
11 183
-32.7%
74,69
835 258 USD
|
11 183
-32.7%
|
74,69
|
835 258 USD
|
|
|
2023-02-08 |
2023-02-06 |
V
Vente
|
Caforio Giovanni
Board Chair and CEO
Administrateur exécutif
|
240 000
-50.4%
74,65
17 916 000 USD
|
240 000
-50.4%
|
74,65
|
17 916 000 USD
|
|
|
2022-11-14 |
2022-11-09 |
V
Vente
|
Powell Ann
EVP, Chief Human Resources
Dirigeant
|
16 250
-32.2%
80,45
1 307 313 USD
|
16 250
-32.2%
|
80,45
|
1 307 313 USD
|
|
|
2022-11-09 |
2022-11-07 |
V
Vente
|
VESSEY RUPERT
EVP, Research & Early Dev.
Dirigeant
|
45 910
-44.6%
78,88
3 621 381 USD
|
45 910
-44.6%
|
78,88
|
3 621 381 USD
|
|
|
2022-09-22 |
2022-09-20 |
VP
Vente planifiée
|
Caforio Giovanni
Board Chair and CEO
Administrateur exécutif
|
25 000
-5.0%
69,71
1 742 750 USD
|
25 000
-5.0%
|
69,71
|
1 742 750 USD
|
|
|
2022-09-16 |
2022-09-15 |
V
Vente
|
Caforio Giovanni
Board Chair and CEO
Administrateur exécutif
|
50 000
-9.1%
71,84
3 592 000 USD
|
50 000
-9.1%
|
71,84
|
3 592 000 USD
|
|
|
2022-09-15 |
2022-09-14 |
V
Vente
|
Powell Ann
EVP, Chief Human Resources
Dirigeant
|
25 000
-33.1%
70,75
1 768 750 USD
|
25 000
-33.1%
|
70,75
|
1 768 750 USD
|
|
|
2022-09-15 |
2022-09-13 |
V
Vente
|
Elkins David V
EVP, Chief Financial Officer
Dirigeant
|
103 951
-46.5%
71,29
7 410 667 USD
|
103 951
-46.5%
|
71,29
|
7 410 667 USD
|
|
